Description

Sunisam 50 mg contains Sunitinib Malate, a multi-targeted receptor tyrosine kinase (RTK) inhibitor widely used in oncology for advanced and metastatic cancers.

🔬 Mechanism of Action

Sunitinib blocks several receptor tyrosine kinases, including:

• VEGFR (Vascular Endothelial Growth Factor Receptors)
• PDGFR (Platelet-Derived Growth Factor Receptors)
• KIT, FLT3, and RET

By inhibiting these pathways, Sunisam 50 mg:

• Reduces tumor blood vessel formation (anti-angiogenic effect)
• Slows cancer cell proliferation
• Limits tumor progression and metastasis

💊 Indications

Sunisam 50 mg is indicated for:

• Advanced Renal Cell Carcinoma (RCC)
• Gastrointestinal Stromal Tumor (GIST) after failure or intolerance to imatinib
• Unresectable or metastatic Pancreatic Neuroendocrine Tumors (pNET)

📌 Key Features

• Strength: 50 mg
• Dosage Form: Oral capsule
• Therapeutic Class: Multi-targeted Tyrosine Kinase Inhibitor
• Typical Regimen: Commonly 4 weeks on treatment followed by 2 weeks off (6-week cycle), as prescribed
• Monitoring: Blood pressure, liver function, thyroid function, and complete blood counts required

⚕️ Benefits

• Effective targeted therapy for multiple advanced cancers
• Oral administration for patient convenience
• Helps delay disease progression
• Reduces tumor vascularization

⚠️ Precautions

• May cause hypertension, fatigue, hand-foot syndrome, and gastrointestinal side effects
• Risk of thyroid dysfunction and cardiac effects
• Dose adjustments may be required based on tolerance
• Regular monitoring essential during treatment
• Use strictly under oncologist supervision

Sunisam 50 mg (Sunitinib Malate Capsules) offers a modern targeted treatment approach for advanced solid tumors, supporting improved disease control and patient outcomes when administered under expert oncology care.